Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.37 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 6/20 | 0.35 |
| ▸ | CTSE | P14091 | 6/20 | 0.35 |
| ▸ | BACE1 | P56817 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2759936 | 1.00 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL23967978 | 0.95 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL2734901 | 0.95 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL19144617 | 0.95 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL10305563 | 0.95 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL10285897 | 0.95 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL13838247 | 0.95 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL18807749 | 0.95 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL20075905 | 0.95 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN | |
| SCHEMBL20133986 | 0.95 | CYP3A4 (0.43) | CYP3A4SSTR2FOLH1TTRREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130157289-A1 | IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157289-A1 | IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | STXBP1, FLOT1, TFIP11 | CYP3A4 4869/4885SSTR2 917/4885FOLH1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.